286 related articles for article (PubMed ID: 3429057)
1. Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur.
Takagi K; Hasegawa T; Ogura Y; Yamaki K; Suzuki R; Satake T; Imaeda N; Mizukami Y
Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):530-5. PubMed ID: 3429057
[TBL] [Abstract][Full Text] [Related]
2. Prediction of steady-state plasma theophylline concentration by Bayesian algorithm.
Imaeda N; Takagi K; Hasegawa T; Saito H; Mizukami Y
Int J Clin Pharmacol Ther Toxicol; 1988 Dec; 26(12):588-93. PubMed ID: 3209276
[TBL] [Abstract][Full Text] [Related]
3. Prediction of steady-state serum theophylline concentration in children by first-order and zero-order absorption models.
Kato Z; Fukutomi O; Yamazaki M; Kondo N; Imaeda N; Orii T
Int J Clin Pharmacol Ther; 1994 May; 32(5):231-4. PubMed ID: 7921516
[TBL] [Abstract][Full Text] [Related]
4. A comparison of absorption rate models in the prediction of steady-state plasma concentrations during oral theophylline administration.
Paterson CM; Hudson SA; Jefferson GC
J Clin Pharm Ther; 1987 Feb; 12(1):39-46. PubMed ID: 3449562
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
Schuppan D; Molz KH; Staib AH; Rietbrock N
Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
[TBL] [Abstract][Full Text] [Related]
6. Absorption of theophylline from conventional and sustained-release tablets.
Fagerström PO; Mellstrand T; Svedmyr N
Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455
[TBL] [Abstract][Full Text] [Related]
7. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
Steinijans VW; Zech K; Fischer R
Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
[TBL] [Abstract][Full Text] [Related]
8. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system.
González MA; Straughan AB
Clin Ther; 1994; 16(5):804-14. PubMed ID: 7859239
[TBL] [Abstract][Full Text] [Related]
9. Absorption of sustained-release theophylline tablets.
Fagerström PO; Heintz L
Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):359-62. PubMed ID: 6885207
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system.
González MA; Kisicki J; Straughn AB
Clin Ther; 1994; 16(4):686-92. PubMed ID: 7982257
[TBL] [Abstract][Full Text] [Related]
11. The influence of enteral feedings on sustained-release theophylline absorption.
Plezia PM; Thornley SM; Kramer TH; Armstrong EP
Pharmacotherapy; 1990; 10(5):356-61. PubMed ID: 2122422
[TBL] [Abstract][Full Text] [Related]
12. Absorption of theophylline from conventional and sustained-release tablets.
Mellstrand T; Svedmyr N; Fagerström PO
Eur J Respir Dis Suppl; 1980; 109():54-60. PubMed ID: 6934088
[TBL] [Abstract][Full Text] [Related]
13. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
14. Effect of food on bioavailability and pharmacokinetics of theophylline following administration of two sustained release dosage forms: Part I.
Ohmori N; Inotsume N; Matsukura M; Higashi A; Iwaoku R; Tobino Y; Nakano M; Matsuda I
Int J Clin Pharmacol Ther Toxicol; 1986 Mar; 24(3):148-52. PubMed ID: 3699941
[TBL] [Abstract][Full Text] [Related]
15. Conversion from intravenous aminophylline to sustained-release theophylline: computer simulation versus in vivo results.
Hatton RC; Gotz VP; Robinson JD; Russell WL; Ryerson GG
Clin Pharm; 1983; 2(4):347-52. PubMed ID: 6883961
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
[TBL] [Abstract][Full Text] [Related]
17. [Absorption profile and absolute bioavailability of a theophylline sustained-release preparation].
Pabst G; Weber W; Barkworth MF; Müller M; Rehm KD
Arzneimittelforschung; 1998 May; 48(5A):574-9. PubMed ID: 9676347
[TBL] [Abstract][Full Text] [Related]
18. Effect of sustained-release on the pharmacokinetics of theophylline in healthy subjects.
Bialer M; Salame K; Raz I
Int J Clin Pharmacol Ther Toxicol; 1985 Dec; 23(12):662-7. PubMed ID: 4093206
[TBL] [Abstract][Full Text] [Related]
19. Study of bioavailability and pharmacokinetics of theophylline following administration of two sustained release dosage forms as assessed by salivary data: Part II.
Ohmori N; Inotsume N; Matsukura M; Higashi A; Iwaoku R; Tobino Y; Nakano M; Matsuda I
Int J Clin Pharmacol Ther Toxicol; 1986 Apr; 24(4):196-201. PubMed ID: 3710632
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation.
Nosaka H; Takagi K; Hasegawa T; Ogura Y; Mizukami Y; Satake T
Int J Clin Pharmacol Ther Toxicol; 1986 Oct; 24(10):528-35. PubMed ID: 3781672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
